US 12,291,552 B2
Chimeric protein in the treatment of amyloidosis
Christophe De Romeuf, Lambersart (FR); Christophe Sirac, Limoges (FR); and Jean-Claude Brouet, Paris (FR)
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITÉDE LIMOGES, Limoges (FR)
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITÉ DE LIMOGES, Limoges (FR)
Filed on Apr. 26, 2022, as Appl. No. 17/729,534.
Application 15/977,489 is a division of application No. 15/032,542, abandoned, previously published as PCT/IB2014/065734, filed on Oct. 31, 2014.
Application 17/729,534 is a continuation of application No. 15/977,489, filed on May 11, 2018, granted, now 11,345,730.
Prior Publication US 2022/0356219 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C07K 16/46 (2006.01); C12N 15/62 (2006.01); G01N 33/68 (2006.01)
CPC C07K 14/4711 (2013.01) [A61K 38/1716 (2013.01); A61K 45/06 (2013.01); C07K 14/47 (2013.01); C12N 15/62 (2013.01); G01N 33/6896 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/2828 (2013.01); G01N 2800/2835 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method for treating in an individual with systemic amyloidosis comprising administering an effective amount of a chimeric protein to the individual, wherein the chimeric protein comprises from N-terminal part to C-terminal part
(i) a human serum amyloid P compound (SAP);
(ii) a first hinge region;
(iii) a first Fc region of a human antibody;
(iv) a spacer chain;
(v) a second hinge region; and
(vi) a second Fc region of a human antibody;
wherein the chimeric protein is a single polypeptide chain comprising a functional dimeric Fc region.